Biotech & Pharma.T.A, Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Biotech & Pharma.T.A,

BIB 79.78

0.0%

Dec 31 4:00 PM EST

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: Jibacoa who wrote (409)	10/9/2003 11:51:35 AM
From: JMarcus	of 3722

A quick OT response on your AVGN comment: <<Although Parkinson's disease is pretty prevalent,I don't know how well this invasive, "pro-drug" approach will be largely accepted.>> The CEO clearly views Avigen as a platform company. His short-term goal isn't sales, but proof of principle. If the AAV vector's viability for gene therapy can be proven, through clinical trials in humans, that proof of principle would be a binary event for Avigen. Partnership deals for new indications would then start lining up at the front door -- leastwise that's the business model he has in mind. Bayer has already given Avigen a bucket-load of cash, so they aren't under pressure to achieve near-term sales. Marc

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next